C
Cyto-Facto
GMP-compliant manufacturing services for gene and cell therapies
About Cyto-Facto
Cyto-Facto Inc., founded in October 2022 by Shin Kawamata, is a contract development and manufacturing organization (CDMO) specializing in gene and cell therapy products. The company spun out of the Foundation for Biomedical Research and Innovation at Kobe (FBRI) in April 2023, taking over the operations of the Cell Therapy Development Center (RDC). The RDC was notably the first site in Asia to commercially produce the CAR-T cell therapy product, Kymriah, for Novartis.
The company provides a range of services including GMP-compliant manufacturing, quality control testing, process development, and consulting for cell and gene preparations. It serves biotechnology and pharmaceutical companies by manufacturing investigational products for clinical trials and commercial-scale products. Cyto-Facto handles therapies using products like CAR-T cells and mesenchymal stem cells (MSC). Its business model is based on offering contract manufacturing (CMO) and contract development and manufacturing (CDMO) services.
A key product developed by the company is CytoFactory 4.0™, a cloud-based, GxP-compliant manufacturing management system designed to digitize and optimize the entire cell manufacturing process. This platform handles everything from raw material intake and inventory control to cell processing, quality testing, and shipment, aiming to reduce costs and improve efficiency. By making manufacturing records fully digital, it also supports regulatory compliance and process improvement.
The founder and CEO, Shin Kawamata, MD, PhD, has an extensive background in pathology, hematology, and stem cell biology, with experience at Novartis Research Institute and Stanford University. He served as the director of the RDC at FBRI before establishing Cyto-Facto. The company has secured Series A and B funding from investors including MPower Partners, D3, Asahi Kasei, Mitsubishi Corporation, and Kobe University Capital.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2025 | $9.2M | $37M | MPower Partners · Sumitomo · FUJIFILM | ↗ |
| SERIES A✓Equity / VC | Apr 2024 | $9.2M | $37M | SMBC Venture Capital · MPower Partners · Mitsubishi · Kobe University Capital | ↗ |
Growth signals
Latest recorded traffic for Cyto-Facto is 1.4K monthly website visits, down 70.2% over the last three months. Cyto-Facto's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cyto-Facto in the Kobe ecosystem
The Cyto-Facto office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
D3
Japan Finance
Kobe Shinkin Bank
Series A7 investors entered at this stage
MPower Partners
SMBC Venture Capital
Mitsubishi- KCKobe University Capital
Mizuho Capital
Sumitomo
FUJIFILM
Other known investors1 additional known investor
Asahi Kasei Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyto-Facto on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyto-Facto’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








